uniQure N.V. (QURE): Depreciation & Amortization
$14.76M
Year ended 2025-12-31
$13.19M
Trailing 12 months to 2026-03-31
+20.0%
3-year compound annual growth
+6.7%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.76M | +16.8% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $12.64M | +6.2% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $11.90M | +39.4% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $8.54M | +17.0% | 2023-02-27, From 2022-01-01 |
| 2021-12-31 | $7.30M | -31.5% | 2023-02-27, From 2021-01-01 |
| 2020-12-31 | $10.65M | +59.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $6.67M | -46.3% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $12.41M | +64.6% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $7.54M | n/a | 2020-03-02, From 2017-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $109.0K | -53.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| Scynexis Inc (SCYX) | 2024-12-31 | $0 | -100.0% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $1.20M | -7.7% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
Compare QURE, PYXS, CVSI, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗